Musculo-skeletal

Soft tissue sarcoma is a complex disease that encompasses a diverse group of relatively rare cancers. In late-stage disease, the prognosis for these patients remains poor, with treated patients with metastatic disease having a median overall survival of around 12–18 months.

Our investigational therapeutic, TLX300 employs antibody-directed targeted radiation, against platelet-derived growth factor receptor alpha (PDGFRα), a receptor located on the surface of a wide range of cell types including in some cancers. Eli Lilly and Company provided a licence for olaratumab, a naked antibody that was formerly marketed as Lartruvo®. We have repurposed olaratumab as a radiopharmaceutical.

Bone pain is frequently experienced by cancer patients with metastatic disease, especially those with prostate, lung and breast cancers. In these cases, disease management often focusses on quality-of-life palliative care.

With our TLX090 investigational therapeutic, Telix is exploring the potential utility of targeted radiation to treat bone metastases and palliate bone pain.

Additionally, Telix is investigating the efficacy of TLX090 in osteosarcoma and Ewing’s sarcoma which are the most common malignancies of the bones in children.

Prior to undergoing haematopoietic stem cell transplantation (HSCT) for the treatment of hematologic malignancies (blood cancers), patients undergo a bone marrow conditioning (BMC) treatment. The current standard of care typically requires BMC with multi-drug chemotherapy regimens. However, these regimens are highly toxic, and patients may not tolerate treatment. This creates an important unmet medical need for more tolerable BMC regimens.

The utilisation of novel cell and gene therapies may also increase by replacing toxic chemotherapy conditioning approaches with bone marrow conditioning.

Our BMC program targets distinct members of cluster of differentiation 66 (CD66), a family of receptors expressed on specific types of immune or blood cells that serve as attractive biomarkers for novel experimental conditioning radiopharmaceuticals – in a variety of haematological diseases (AML, MM, SALA and pediatric leukemia).